Want to see JP:4519 full AI Analyst Report?
Chugai Pharmaceutical Co (4519) AI Stock Analysis
Top Page
Chugai Pharmaceutical Co
(TSE/TYO:4519)
The score is driven primarily by standout financial strength and profitability paired with a very conservative balance sheet and strong cash generation. Earnings-call commentary further supports the outlook via ahead-of-plan performance and pipeline/regulatory progress, while the main constraint is a mixed technical picture (still below longer-term moving averages) and only moderate valuation on P/E despite a solid dividend yield.
Chugai Pharmaceutical Co (4519) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 69.54B
- Dividend Yield
- 3.12%
- Average Volume (3M)
- 2.96M
- Price to Earnings (P/E)
- 22.3
- Beta (1Y)
- 0.62
- Revenue Growth
- 16.53%
- EPS Growth
- 26.83%
- Country
- Japan
- Employees
- 5,104
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - General
Chugai Pharmaceutical Co Business Overview & Revenue Model
Company Description
Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and internati...
How the Company Makes Money
Chugai primarily makes money by generating revenue from prescription pharmaceuticals and related rights. Key revenue streams include: (1) Product sales: revenue from selling branded prescription drugs, including medicines that Chugai develops and mar...
Chugai Pharmaceutical Co Earnings Call Summary
The call was strongly positive overall. Revenue and core operating profit grew substantially, the company expects to exceed its full-year forecast, overseas products and royalties performed well, and the pipeline delivered approvals, filings, positive clinical readouts, and important progress for Hemlibra and Divarasib. The main challenges were pricing and generic pressure, higher costs, one-time domestic shipment timing, discontinued GYM329 obesity and LUNA18 programs, selected product declines, and reduced cash following large tax and special dividend payments. Highlights significantly outweighed lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
The company said it is tracking well against its full year forecast and expect to exceed it, with Actemra full year sales expected to exceed the forecast by about or more than JPY 10 billion, while Hemlibra full year sales are expected to come in line with the forecast and overseas exports are likely to achieve the full year forecast; 75% is the benchmark for nine-month progress, Divarasib is planned to be filed for approval in Japan within this year, the Hemlibra auto-injector is targeted for launch globally and in Japan in 2027, its dosing should be completed within 10 seconds versus about 5 minutes for vial preparation, it is expected to maintain the current level of profit with nothing material affecting the cost ratio, 6 more projects are scheduled for 2026, and trontinemab has been brought forward to 2028 from 2029 and beyond.
Chugai Pharmaceutical Co Financial Statement Overview
Summary
High-quality fundamentals: excellent profitability (very high gross and net margins), exceptionally conservative balance sheet with minimal leverage and strong ROE, and strong absolute cash generation. Offsets are recent free cash flow growth decline (TTM -10.3%) and some revenue volatility (notably the 2023 contraction).
Income Statement
92Very PositiveBalance Sheet
95Very PositiveCash Flow
86Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.41T | 1.26T | 1.17T | 1.11T | 1.26T | 999.76B |
| Gross Profit | 1.01T | 894.25B | 830.75B | 693.01B | 783.06B | 660.27B |
| EBITDA | 705.77B | 631.37B | 574.80B | 475.64B | 562.66B | 450.30B |
| Net Income | 503.71B | 434.01B | 387.32B | 325.47B | 374.43B | 303.00B |
Balance Sheet | ||||||
| Total Assets | 2.37T | 2.47T | 2.21T | 1.93T | 1.87T | 1.54T |
| Cash, Cash Equivalents and Short-Term Investments | 869.00B | 979.70B | 996.35B | 738.98B | 503.11B | 471.97B |
| Total Debt | 16.14B | 0 | 10.90B | 13.46B | 14.11B | 16.04B |
| Total Liabilities | 285.78B | 442.86B | 306.87B | 306.97B | 445.37B | 350.68B |
| Stockholders Equity | 2.09T | 2.03T | 1.90T | 1.63T | 1.42T | 1.19T |
Cash Flow | ||||||
| Free Cash Flow | 363.25B | 313.18B | 396.68B | 335.67B | 172.87B | 206.76B |
| Operating Cash Flow | 438.72B | 389.45B | 447.60B | 409.93B | 244.11B | 279.63B |
| Investing Cash Flow | -151.86B | -204.87B | -227.37B | -37.29B | -145.99B | -118.93B |
| Financing Cash Flow | -363.62B | -307.46B | -141.01B | -139.33B | -145.64B | -107.41B |
Chugai Pharmaceutical Co Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4519, the sentiment is Positive. The current price of 6822.00 is above the 20-day moving average (MA) of 6382.80, above the 50-day MA of 6562.92, and below the 200-day MA of 7752.05, indicating a neutral trend. The MACD of 78.26 indicates Negative momentum. The RSI at 60.94 is Neutral, neither overbought nor oversold. The STOCH value of 67.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4519.
Chugai Pharmaceutical Co Peers Comparison
Overall Rating
- JP:451983Outperform
JP:452372Outperform
JP:452870Outperform
JP:450268.15Neutral
JP:456868Neutral
JP:450364Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4519 | 83Outperform | JPY 11.23T | 22.29 | 25.03% | 3.12% | 16.53% | 26.83% |
| JP:4523 | 72Outperform | JPY 1.42T | 33.66 | 4.77% | 3.17% | 6.73% | -15.79% |
| JP:4528 | 70Outperform | JPY 1.06T | 14.21 | 8.69% | 3.55% | -2.48% | 53.80% |
| JP:4502 | 68Neutral | JPY 10.62T | 27.16 | 5.07% | 3.04% | 6.25% | 15.40% |
| JP:4568 | 68Neutral | JPY 5.01T | 20.85 | 16.51% | 3.23% | 16.98% | 9.22% |
| JP:4503 | 64Neutral | JPY 4.63T | 12.62 | 20.41% | 3.07% | 16.93% | 347.13% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4519 | Chugai Pharmaceutical Co | 6822.00 | -42.30 | -0.62% | |
| JP:4503 | Astellas Pharma | 2571.00 | 1008.62 | 64.56% | |
| JP:4568 | Daiichi Sankyo Company | 2754.00 | -802.20 | -22.56% | |
| JP:4523 | Eisai Co | 5052.00 | 628.79 | 14.22% | |
| JP:4528 | ONO Pharmaceutical Co | 2256.00 | 439.61 | 24.20% | |
| JP:4502 | Takeda Pharmaceutical Co | 6651.00 | 2639.32 | 65.79% |
Chugai Pharmaceutical Co Corporate Events
Chugai Highlights FX Impact in Nine-Month 2026 IFRS Results
Chugai Pharmaceutical has released supplementary consolidated financial materials for the nine months ended September 30, 2026, highlighting the foreign exchange assumptions and actual rates used in its IFRS reporting. The document underscores how we...
Chugai Pharmaceutical Posts Strong Nine-Month Earnings and Confirms 2026 Guidance
Chugai reported strong results for the nine months ended September 30, 2026, with revenue rising 17.2% year on year to ¥1,068.1 billion and operating profit up 21.6% to ¥522.6 billion. Net income attributable to shareholders climbed 22.8% t...
Chugai Highlights Inclusion in Roche’s Q3 2026 Results
F. Hoffmann-La Roche has reported its third quarter 2026 sales, covering the period from January 1 to September 30, 2026, and has made its investor update and presentation materials available on its website. Chugai’s performance for the same pe...
Chugai Takes Back Rights to Emugrobart as Roche Exits Obesity Program, Revives SMA Focus
Chugai Pharmaceutical said Roche will discontinue development of emugrobart (GYM329) for obesity after interim Phase II data suggested the drug, used with GLP-1/GIP agonists, was unlikely to achieve clinically meaningful weight loss despite a favorab...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 29, 2026